LONG-TERM FOLLOW-UP OF PATIENTS WITH MEDULLARY CARCINOMA OF THE THYROID

Citation
U. Bergholm et al., LONG-TERM FOLLOW-UP OF PATIENTS WITH MEDULLARY CARCINOMA OF THE THYROID, Cancer, 79(1), 1997, pp. 132-138
Citations number
25
Categorie Soggetti
Oncology
Journal title
CancerACNP
ISSN journal
0008543X
Volume
79
Issue
1
Year of publication
1997
Pages
132 - 138
Database
ISI
SICI code
0008-543X(1997)79:1<132:LFOPWM>2.0.ZU;2-N
Abstract
BACKGROUND. All patients with medullary carcinoma of the thyroid (MCT) diagnosed in Sweden during 1959 through 1981 were identified. There w ere 113 males and 134 females with a mean age of 51.6 years (range, 11 -85 years). The cohort was followed with regard to survival to identif y prognostic factors. The results 5 and 10 years after diagnosis have been presented previously. METHODS. The purpose of this study was to e xamine to what extent those prognostic factors found in the authors' p revious analyses remained independent prognostic factors for survival 10 years or longer after diagnosis. The follow-up period was extended an additional 5 years and ranged between 11 and 32 years. RESULTS. The relative survival rate was 69.2% and 64.7%, respectively, 10 and 15 y ears after diagnosis. The survival rate was worse after excluding thos e patients with a family history of MCT (60.8% and 53.7%, respectively , 10 and 15 years after diagnosis). In multivariate analyses, age, tum or size, stage of the disease at diagnosis, tumor amyloid content and an euploid DNA pattern were found to be independent prognostic factors . However, in analyses of survival 10 years or longer after diagnosis only stage, tumor size, and age remained independent prognostic factor s. CONCLUSIONS, There is still an excess mortality 10 years or longer after a diagnosis of MCT. However, the authors identified 3 groups of patients in whom the survival 10 years or longer after diagnosis did n ot differ from that of the general population: patients with a family history of MCT detected by screening, those with tumor size < 1 cm, or those with early stage disease at diagnosis. (C) 1997 American Cancer Society.